1. Home
  2. TREO vs NSRX Comparison

TREO vs NSRX Comparison

Compare TREO & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactical Resources Corp. Common Shares

TREO

Tactical Resources Corp. Common Shares

N/A

Current Price

$2.02

Market Cap

41.9M

ML Signal

N/A

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.09

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TREO
NSRX
Founded
N/A
2019
Country
Canada
Israel
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.9M
38.9M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
TREO
NSRX
Price
$2.02
$3.09
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $19.67
AVG Volume (30 Days)
★ 40.4K
21.1K
Earning Date
11-06-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.05
$1.98
52 Week High
$5.90
$9.50

Technical Indicators

Market Signals
Indicator
TREO
NSRX
Relative Strength Index (RSI) 22.41 34.65
Support Level N/A $2.97
Resistance Level $3.50 $3.60
Average True Range (ATR) 0.41 0.25
MACD -0.05 -0.07
Stochastic Oscillator 0.87 10.94

Price Performance

Historical Comparison
TREO
NSRX

About TREO Tactical Resources Corp. Common Shares

Tactical Resources Corp is an exploration & development company focused on the rare earth elements (REE) that drive the green technologies of the future. Its projects include Lac Ducharme Project, Sierra Blanca Quarry Project, and Peak Project.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: